Selumetinib

Target: MEK | Disease State: NF1

Introduction / Brief Description

Selumetinib is an oral small molecule MEK inhibitor invented by Array and licensed to AstraZeneca. AstraZeneca is responsible for development and commercialization of selumetinib.

Selumetinib targets key enzymes in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of this pathway has been shown to occur in many conditions, including neurofibromatosis type 1 (NF1).

A registration trial is advancing with selumetinib in patients with neurofibromatosis type 1 (NF1).

NF1

NF is a genetic disorder that can cause typically non-malignant tumors, or PNs, to grow on nerves throughout the body. These tumors can be very disfiguring, painful, and disabling. Most tumors are inoperable, while some patients undergo often-repeated surgical procedures. NF1 also causes a number of other health issues, including deafness, blindness, learning disabilities, bone abnormalities, and sometimes cancer. PNs exhibit the most rapid growth in young children, and therefore early intervention in children with growing PNs may result in the greatest clinical benefit. NF1, which appears in approximately one in 3,000 people, or 100,000 in the United States, has no cure. 

Clinical Trials

Trial Data
Trial Title
Program: Selumetinib (AZD6244)
Phase: 2
Status: Recruiting
Disease: Neurofibromatosis Type 1
Sponsor: National Cancer Institute
Trial Information: NCT01362803
Trial Title: AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
Program: Selumetinib (AZD6244)
Trial Information: ClinicalTrials.gov
Trial Title: Other clinical trials

To learn more about selumetinib clinical trials, click here.

Publications and Presentations

Selumetinib

09/28/2014

ESMO

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Selumetinib

09/28/2014

ESMO Congress 2014 - Madrid, Spain

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Selumetinib

06/02/2014

American Society of Clinical Oncology Meeting

A Phase I Study of the MEK1 Inhibitor Selumetinib (AZD6244) Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PNs)

L. Marcus, et al.

Selumetinib

06/08/2013

Children’s Tumor Foundation’s Neurofibromatosis Conference

A Phase I Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib) in Children and Young Adults with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas (PN)

B. Widemann, MD, et al.

Selumetinib

06/01/2013

American Society of Clinical Oncology Annual Meeting

Phase II Study of Selumetinib vs Temozolomide in Patients with Advanced Uveal Melanoma (CTEP #8443)

R. D. Carvajal


To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.